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EXPENSIVE CEREBRAL BLOOD FLOW MEASUREMENTS
ALONE ARE USELESS AND MISINFORMATIVE IN
COMATOSE PATIENTS
A comprehensive alternative
Julio Cruz1
ABSTRACT - Since the first report addressing quantification of cerebral blood flow (CBF), concomitant assessment
of cerebral oxygen consumption was also carried out. Over the years, however, some investigators have
emphatically and mistakenly addressed cerebral ischemia in comatose patients, on the basis of CBF
measurements alone. In contrast, we have repeatedly reported that ischemia in these patients must be precisely
evaluated based on CBF-metabolism coupling or uncoupling, rather than CBF alone. Based on these previous
findings, we therefore propose a comprehensive alternative approach, namely the evaluation of brain ischemia
in comatose patients based on cerebral metabolic parameters, such as cerebral extraction of oxygen or cerebral
lactate release, without expensive CBF measurements.
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Medidas dispendiosas apenas de fluxo sanguíneo cerebral são inúteis e desinformativas em estados de
coma: uma alternativa abrangente
RESUMO - Desde o primeiro artigo apresentando quantificação de fluxo sanguíneo cerebral (FSC), também se
avaliou o consumo cerebral de oxigênio. Todavia, ao longo dos anos, alguns investigadores têm enfaticamente
e erroneamente destacado a isquemia cerebral em pacientes comatosos, baseando-se apenas em medidas do
FSC. Em contrapartida, temos repetidamente destacado que a avaliação de isquemia cerebral nestes pacientes
deve ser baseada no conceito de acoplamento ou desacoplamento entre metabolismo cerebral e FSC, ao invés
de alterações no FSC apenas. Baseando-se nestes achados prévios, aqui propomos uma abordagem alternativa
e abrangente, a qual envolve a avaliação de isquemia cerebral em pacientes comatosos baseando-se em
parâmetros metabólicos cerebrais, tais como a extração cerebral de oxigênio ou a liberação cerebral de lactato,
sem medidas dispendiosas de FSC.
PALAVRAS-CHAVE: diferença artério-jugular de lactato, isquemia cerebral, fluxo sanguíneo cerebral, extração
cerebral de ôxigenio, coma.
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Since the pioneering work of Kety and Schmidt1,
addressing quantification of cerebral blood flow
(CBF), concomitant assessment of the cerebral me-
tabolic rate of oxygen consumption (CMRO2) was
also established. CBF was precisely quantified as the
integrated arteriojugular difference of nitrous oxide
over approximately 10 minutes (the height-over-
area method of quantification), whereas CMRO2
was calculated as the product of CBF and the arteri-
ojugular oxygen content difference (AVDO2). The lat-
ter parameter had already been introduced in the
pertinent literature by another pioneering work of
Gibbs and coworkers2.
Over the years, nearly all alternative techniques
proposed for CBF quantification adopted the nor-
mal CBF values reported by Kety and Schmidt for
validation, even those involving modern and sophis-
ticated positron emission tomography (PET) scan-
ning. Therefore, arteriojugular measurements have
been regarded as highly accurate by most investiga-
tors, not only for cerebral metabolic assessment but
also for CBF measurements.
In recent years, however, stable xenon compute-
rized tomography (CT) CBF measurements became
available, and a number of studies have emphatically
and mistakenly addressed global or regional cere-
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bral ischemic changes in comatose patients3-5. The
most elementary mistake in all these papers is that
ischemia was defined as CBF levels of 18 ml/100 g/
min or less, based on previously reported work ad-
dressing ischemic changes at such CBF levels, but in
the awake monkey brain6.
Because the awake brain presents with normal
oxygen consumption, it is expected that a reduction
in CBF from normal 50 ml/100 g/min to 18 ml/100
g/min may, in fact, lead to cerebral ischemic changes.
Unlike the awake monkey brain, however, CBF reduc-
tions to approximately 20 ml/100 g/min in awake
human brain have not resulted in any neurological
deficit7. In this latter study by Finnerty and cowor-
kers, cerebral oxygen extraction increased to com-
pensate for the CBF reduction, but no evidence of
cerebral ischemia was found on clinical grounds.
Because cerebral oxygen consumption has been
invariably reported as largely decreased in comatose
patients8-15, and by simply applying to cerebral phy-
siology the basic notion of proportionality, it there-
fore became clear to us that ischemic CBF thresholds
in the comatose brain must be lower than 20-18 ml/
100 g/min. In this respect, we first reported a well
documented case where CBF spontaneously dropped
to as low as 10 ml/100 g/min in a comatose patient,
and excellent neurological recovery could still be ob-
served after 45 days only9. Most recently, Diringer
and coworkers16 have intentionally dropped regio-
nal CBF levels to as low as 8 ml/100 g/min, also in
comatose patients, and found no metabolic evidence
of ischemia based on sophisticated PET scanning.
From the above discussion, it becomes clear that
all studies addressing CBF measurements alone
(without concomitant metabolic data) have invaria-
bly introduced mistaken, perhaps intentional misin-
formation in the field of cerebral hemodynamics app-
lied to comatose patients. This is particularly true for
studies involving stable xenon CT-CBF measurements3-5,
besides less frequently used single photon emission
computerized tomography (SPECT) CBF studies, which
simply do not provide any metabolic information.
CBF-metabolism coupling
As described earlier, AVDO2 is the ratio of CMRO2
to CBF. However, we have found that AVDO2 frequen-
tly underestimates cerebral oxygen extraction in mild
or profound acute anemia, a frequent finding during
intensive care10,17. We have therefore introduced in
the pertinent literature two novel parameters, which
were termed cerebral extraction of oxygen (CEO2)
and cerebral consumption of oxygen (CCO2)
10. CEO2
(the arteriojugular oxyhemoglobin saturation diffe-
rence) and CCO2 (the product of CBF and CEO2) are
accurate variables in either anemic or non anemic
conditions, and therefore became better alternative
measurements than the conventional AVDO2 and
CMRO2. These interrelationships are expressed by the
following equation:
CEO2 = CCO2 / CBF * 100
The simple inspection of this equation reveals
that, without the need to measure CBF and CCO2, a
normal (or therapeutically normalized) CEO2 value
will accurately indicate adequate global CBF-
metabolism coupling. Accordingly, an increased
(widened) CEO2 will indicate a condition of relative
cerebral hypoperfusion, where CBF is reduced in
relation to the oxygen demand, consistent with a pre-
ischemic or truly ischemic finding, depending on the
magnitude of the CEO2 increase. In our experience,
the normal CEO2 ranges are 24-42% in adults
10,18-21
and 17-35% in children19,22, so that values above the
upper normal limits would require therapies to increase
CBF (again, without the need for CBF measurements).
Conversely, a decreased (narrowed) CEO2 will
indicate a condition of relative cerebral hyperperfu-
sion, where CBF is increased relative to oxygen de-
mand. Under these circumstances, cerebral vasocons-
trictive therapies may be indicated, especially in the
presence of elevated intracranial pressure (ICP).
Phasic physiological changes
Lassen23 first reported abnormally increased CBF
following clinically suspected cerebral hypoxic or
ischemic events, a surprising condition defined as
luxury perfusion syndrome. Indeed, based on Las-
sens experience, this secondary hyperperfusional
state may be expected in patients with acute ischemic
stroke, following an initial CBF reduction. The exact
underlying mechanism responsible for such phasic
changes remains unknown, however.
In comatose patients with severe acute brain trau-
ma, we first reported in recent studies that phasic
CEO2 changes are also frequent, both in adults
20,21
and children22. Unlike Lassens experience with CBF
measurements, we did not have clear clinical evi-
dence of an initial hypoxic or ischemic insult, but
normal or mildly increased CEO2 values on the first
postinjury day were frequently replaced by decreased
CEO2 during most of the acute phase of illness
20-22.
These important phasic changes, however, have not
even been addressed by those who have only focused
on reduced CBF alone (without mandatory metabolic
data), and have invariably and mistakenly addressed
ischemia in a grossly biased fashion3-5.
Consciousness versus coma
The aforementioned controversial findings must
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be interpreted on the basis of the patients level of
consciousness, as well as the disease process. Indeed,
if a patient becomes unconscious immediately after
the brain insult (such as severe trauma), a global
decrease in CCO2 is expected, until the patient reco-
vers consciousness and CCO2 physiologically increa-
ses. Under these circumstances, it is just expected
that truly ischemic CBF thresholds will not be found,
at least during intensive care. Indeed, the metabolic
parameters involving arteriojugular oxygen (CEO2)
and lactate differences have recently essentially ruled
out cerebral ischemia in two large series of patients
reported by our team20,21.
In the initially conscious patient (such as in ische-
mic stroke or cerebral vasospasm in aneurysmal suba-
rachnoid hemorrhage), however, ischemic CBF
thresholds are expectedly higher than in the initially
comatose patient, because CCO2 is initially normal.
Accordingly, therapies to increase CBF are logical in
most of these conscious patients. In addition, if there
is a clear cause-and-effect relationship between acu-
tely reduced CBF and the state of coma or even just
focal neurological deficits, manipulating CBF upward
would always seem advisable. Once the state of coma
is diagnosed without clear evidence that reduced CBF
was the triggering event, however, therapies aiming
at upward CBF changes would seem to be ilogical,
because CBF would just exceed the globally reduced
CCO2 and, in patients with acutely decreased
cerebrospinal fluid spaces, increasing CBF therapeu-
tically may induce dangerous ICP increases.
Therefore, on practical grounds, it is extremely
difficult to make decisions regarding therapeutic up-
ward CBF manipulations in a comatose patient, whe-
reas such decision-making process is easy in the
conscious patient, especially in the presence of loca-
lizing neurological signs and a well established diag-
nosis showing that reduced CBF was the primary ad-
verse event. While this condition is clear in acute
ischemic stroke and vasospasm following aneurysmal
subarachnoid hemorrhage, the same is not true in
many comatose patients who present at the hospi-
tal with other disease processes.
Diagnosing brain ischemia
Based on our extensive previously published
experience9-11,18-22, we hereby propose that CBF
measurements be definitively abandoned, and repla-
ced by cerebral metabolic parameters. For global as-
sessment, CEO2 has been the most practical and inex-
pensive option, for both adults10,18,20,21 and children22.
The arteriojugular lactate difference (AVDL) may also
be used20,21, but it is more expensive and technically
more cumbersome. The combination of CEO2 and
AVDL measurements certainly and accurately will
inform about global brain ischemia or its reciprocal
(relative hyperperfusion), as we have recently
reported for the first time in adults20,21. AVDL mea-
surements are not yet used for children, because of
the lack of normal data in the pertinent literature.
For regional information, PET scanning is the best
technique, but it is expensive, involves lenghty pro-
cedures, and is formally contraindicated for patients
with suspected or confirmed intracranial hyperten-
sion, because the patients head is placed flat for
prolonged periods. The same applies to functional
magnetic resonance imaging, which also provides
regional cerebral metabolic information, but cannot
be used for these unstable patients, because dange-
rous ICP increases may occur due to lowering the
head as well.
Finally, regional information addressing CBF alo-
ne, as described earlier, should be definitively aban-
doned, not only because it provides absolutely no
information with respect to CBF-metabolism
coupling, but also because unstable patients with
intracranial hypertension will be at increased risk of
developing lethal tentorial herniation, for having the
head positioned flat during the CT-CBF studies (as
also happens with PET and functional magnetic
resonance imaging). Therefore, on practical grounds,
regional information regarding brain ischemia is still
an impossible dream and, besides clinical informa-
tion and cerebral angiography, true metabolic con-
firmation of regional cerebral ischemia would appear
to be unfeasible under most circumstances, at least
for acutely unstable patients.
Transcranial doppler is not an alternative
Unlike suggested by some investigators, transcra-
nial doppler (TCD) assessment is not regional, but
segmentary, involving only large intracranial vessels.
Because cerebrovascular resistance may change at
the microcirculatory level, in response to macrocircu-
latory abnormalities detected by TCD, true tissue
ischemia cannot be confirmed by TCD measure-
ments, in any disease process. This is particularly true
in comatose patients, because global cerebral meta-
bolic supression represents a general rule and, the-
refore, even gross TCD abnormalities may be clinically
irrelevant in comatose patients. In conscious or semi-
comatose patients, however, serial (not single) TCD
assessment may allow for better selection of candi-
dates to undergo cerebral angiography and, even-
tually, angioplasty in cerebral vasospasm associated
with aneurysmal subarachnoid hemorrhage. In con-
trast, TCD diagnosis does not apply to brain trauma
or even acute ischemic stroke, where TCD has not
been demonstrated as capable of changing thera-
peutic decisions.
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An additional limitation of TCD in comatose pa-
tients is that changes in flow velocity, sometimes
speculated as indicative of vasospasm, may just
represent reduced CBF which, at the microcirculatory
level (not assessable by TCD measurements), repre-
sents nothing but normal coupling between low blo-
od flow and reduced CCO2.
Dangerous brain tissue probes
In recent years, acute placement of brain tissue
probes has been proposed, focusing on microdialysis
(for measurements of brain tissue lactate, glucose,
etc), focal oxygen tension monitoring, or even focal
brain temperature assessment. Even though these
expensive monitoring devices have been approved
for clinical use, such approval should never have
occurred, because normal values are not even known
for any type of brain tissue probe measurement.
Indeed, healthy human beings will never volunteer
to have their heads open for any type of brain tissue
probe to be placed in their brains.
Despite the total lack of knowledge regarding
normal physiological values by these probes, focal
brain ischemia has been reported in terms of low
oxygen and high lactate24. In this respect, it is
obvious that any brain tissue probe causes focal
microvascular compression and distortion, which
may well explain focal microcirculatory compressive
hypoxia, with resulting increase in lactate concen-
tration, findings that would be just artifactual, howe-
ver. Another highly biased report addressed focal
brain ischemia associated with hyperventilation,
even when jugular oxygen values were normal or
high, but the brain tissue oxygen probe showed so-
called critically low levels25. Because this kind of
intentional misinformation may have serious implica-
tions with respect to patient care, a thorough discus-
sion regarding the total lack of validation of any type
of brain tissue probe has recently been published by
our team26. It is therefore hoped that all these brain
tissue probes will be definitively abandoned, because
they are highly invasive and normal values are not even
known, and their use has obviously been recently
defined as animal experimentation in humans26.
Future prospects
In light of the aforementioned clinically relevant
limitations in assessing regional cerebral metabolic
patterns associated with ischemia, it remains for glo-
bal arteriojugular measurements to be further ex-
plored as clinically reliable guides for a variety of
therapeutic approaches, which may be adopted in a
broad spectrum of acute disease processes, whereas
truly reliable regional information will still require
future alternative methodologies and techniques, es-
pecially for acutely unstable patients with suspected
or confirmed intracranial hypertension. For more sta-
ble patients, however, currently available techniques
(such as PET or functional magnetic resonance ima-
ging) are helpful but expensive, so that they have
not yet become routine procedures in most hospitals
worldwide.
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